The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 25, 2024

Filed:

Oct. 10, 2019
Applicant:

Intarcia Therapeutics, Inc., Boston, MA (US);

Inventors:

William Blackwell, Boston, MA (US);

Ved P. Srivastava, Boston, MA (US);

James M. Way, Boston, MA (US);

Assignee:

I2O THERAPEUTICS, INC., Cambridge, MA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/575 (2006.01); A61K 9/00 (2006.01); A61K 38/00 (2006.01); A61P 3/04 (2006.01); A61P 3/10 (2006.01);
U.S. Cl.
CPC ...
C07K 14/575 (2013.01); A61K 9/0004 (2013.01); A61K 9/0019 (2013.01); A61P 3/04 (2018.01); A61P 3/10 (2018.01); A61K 38/00 (2013.01);
Abstract

This invention relates to isolated polypeptides that are analogs of human amylin. The disclosed amylin analog polypeptides have beneficial physicochemical properties relative to endogenous amylin, such as longer elimination half-lives (t) and improved solubility and thermal stability. This invention also relates to methods of using presently disclosed amylin analog polypeptides in a variety of therapeutic indications, as well as methods of producing the same. The disclosed amylin analog polypeptides are particularly useful in methods of treating metabolic diseases or disorders, such as types 1 and 2 diabetes, and providing weight loss.


Find Patent Forward Citations

Loading…